

Financial Presentation

NYSE: SMIHKSE: 981SMIC Investor Relations

October 2013

Safe Harbor Statements Under the Private Securities Litigation Reform Act of 1995

This presentation contains, in addition to historical information, "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements under "Fourth Quarter 2013 Guidance", and the statements and chart regarding our future 2013 capital expenditures, are based on SMIC's current assumptions, expectations and projections about future events. SMIC uses words like "believe." "anticipate." "intend," "estimate," "expect," "project" and similar expressions to identify forward-looking statements, although not all forwardlooking statements contain these words. These forward-looking statements involve significant risks, both known and unknown, uncertainties and other factors that may cause SMIC's actual performance, financial condition or results of operations to be materially different from those suggested by the forward-looking statements including, among others, risks associated with the global economic slowdown, orders or judgments from pending litigation and financial stability in end markets. Investors should consider the information contained in SMIC's filings with the U.S. Securities and Exchange Commission (SEC), including its annual report on 20-F filed with the SEC on April 15, 2013, especially the consolidated financial statements, and such other documents that SMIC may file with the SEC or The Hong Kong Stock Exchange Limited ("SEHK") from time to time, including current reports on Form 6-K. Other unknown or unpredictable factors also could have material adverse effects on SMIC's future results, performance or achievements. In light of these risks, uncertainties, assumptions and factors, the forward-looking events discussed in this presentation may not occur. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date stated, or if no date is stated, as of the date of this presentation. Except as may be required by law, SMIC undertakes no obligation and does not intend to update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Non-Generally Accepted Accounting Principles ("Non-GAAP") Financial Measures

To supplement SMIC's consolidated financial results presented in accordance with IFRS, SMIC uses in this presentation measures of operating results that are adjusted to exclude wafer shipments from Wuhan Xinxin Semiconductor Manufacturing Corporation ("Wuhan Xinxin"), which SMIC began gradually phasing out in 3Q13. This presentation includes non-GAAP revenue, non-GAAP cost of sales and non-GAAP gross margin. It also includes fourth quarter 2013 guidance for non-GAAP revenues and non-GAAP gross margin, which exclude such shipments, and for non-GAAP operating expenses, which is adjusted to exclude the effect of foreign exchange, employee bonus accrual, funding of R&D contracts from the government and gain from the disposal of living quarters. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS.

SMIC believes that use of these non-GAAP financial measures facilitates investors' and management's comparisons to SMIC's historical performance. The Company's management regularly uses these non-GAAP financial measures to understand, manage and evaluate the Company's business and make financial and operational decisions.

3Q13 Financial Highlights

Revenue including wafer shipments from Wuhan Xinxin was \$534.3 million

increased 15.8% year over year

- decreased 1.3% quarter over quarter

Record-high Non-GAAP revenue excluding wafer shipments from Wuhan Xinxin of \$503.7 million

- increased 21.7% year over year
- increased 0.4% quarter over quarter

Gross margin including wafer shipments from Wuhan Xinxin was 21.0%

- compared to 27.5% in 3Q12
- compared to 25.0% in 2Q13

Non-GAAP gross margin excluding wafer shipments from Wuhan Xinxin was 22.1%

- compared to 30.4% in 3Q12
- compared to 26.7% in 2Q13

3Q13 Financial Highlights

Sixth consecutive quarter of positive profit attributable to SMIC was \$42.5 million

- compared to profit of \$12.0 million in 3Q12
- compared to profit of \$75.4 million in 2Q13

Revenue from 40/45 nm applications increased to a record 15.7% of wafer revenue

compared to 0.8% in 3Q12

compared to 10.0% in 2Q13

Cash and bank balances increased to \$473.5 million

- compared to \$231.8 million in 3Q12
- compared to \$263.0 million in 2Q13


Revenue from China-based customers increased to 42.1% of overall revenue, an alltime high

- compared to 35.3% in 3Q12
- compared to 40.9% in 2Q13





Non-GAAP revenue excluding wafer shipments from Wuhan Xinxin



Revenue from wafer shipments from **Wuhan Xinxin** was **\$30.6 million** in 3Q13. The Company began phasing out wafer shipments from Wuhan Xinxin in 3Q13.

Balance Sheet Highlights

(US\$ thousands)	For the three months ended			
	Sept 30, 2013	June 30, 2013		
Cash and bank balances	473,507	262,955		
Restricted Cash	195,813	214,430		
Trade and other receivables	396,108	472,426		
Inventories	289,954	308,328		
Other Assets	3,065,700	3,043,560		
Total Assets	4,421,082	4,301,699		
Short-term borrowings	548,385	586,425		
Long-term borrowings	553,435	474,692		
Total Debt	1,101,820	1,061,117		
Total Liabilities	1,861,701	1,897,961		
Total Equity	2,559,381	2,403,738		
Debt/Equity Ratio*	43.1%	44.1%		


* Calculated based on (Total Debt) / (Total Equity)



Cash Flow Highlights


(US\$ thousands) For the three months ended Sept 30, 2013 June 30, 2013 Cash and bank balances, 262,955 292,932 beginning of period Net cash generated from 269,581 108,360 operating activities Net cash used in investing (213,133) (242, 559)activities Net cash (used in) 154,045 generated from financing 104,167 activities Net increase (decrease) in 210,552 (29, 977)cash and bank balances Cash and bank balances, 473,507 262,955 end of period

Cash Flow from Operations






Total Revenue Breakdown by Applications







Revenue (\$US mil)

SЛ

Total Revenue Breakdown by Geography


North America China Eurasia 9.5% 10.8% 10.0% 10.8% 11.9% 35.3% 34.8% 38.6% 40.9% 42.1% 55.2% 54.4% 51.4% 48.3% 46.0% 3Q12 4Q12 1Q13 2Q13 3Q13


3Q 13 vs. 2Q 13

China

North America

3Q13





Eurasia

300

250

200

150

100

50


0

2Q13


Wafer Revenue Breakdown by Technology

0.25 / 0.35um 90nm 55 / 65nm 0.15 / 0.18um 0.13um 40 / 45nm 0.8% 2.6% 6.4% 10.0% 15.7% 9.4% 8.0% 6.7% 4.6% 10.5% 4.7% 10.1% 11.8% 10.2% 10.7% 37.5% 39.9% 39.9% 40.1% 38.4% 57% 1 00/ 1 20/2 2 00/ 1 00/ 3Q12 4Q12 1Q13 2Q13 3Q13

3Q 13 vs. 2Q 13



Capacity, Utilization and Shipment



	3Q12	4Q12	1Q13	2Q13	(3Q13
Shanghai Mega Fab (8")	90,000	90,000	90,000	90,000	90,000
Shanghai 12-inch Fab (12")	-	6,000	6,290	8,000	11,000
Beijing Mega Fab (12")	35,000	35,000	36,000	36,000	36,000
Tianjin Fab (8")	37,000	37,000	34,450	34,500	36,000
Monthly Capacity (8-inch equivalent wafers)	205,750	219,250	219,600	223,500	231,750
Wafer Shipment	605,543	608,372	631,776	687,651	653,090
Utilization Rate ⁽¹⁾	92.0%	90.5%	89.0%	98.5%	88.2%

(1) Capacity utilization rate is reported based on total equivalent wafers out divided by estimated total quarterly capacity

4Q 2013 Guidance and 2013 Capex Guidance

	4Q 2013 Guidance	2013 Capex Guidand (US\$mm)	
Non-GAAP Revenue excluding wafer shipments from Wuhan Xinxin	Flat to -4.5%		
Revenue including wafer shipments from Wuhan Xinxin	-4.5% to -9%	\$675 ⁽²⁾	
Non-GAAP Gross Margin excluding wafer shipments from Wuhan Xinxin	19.0% to 22.0%	Foundry Operation	
Gross Margin including wafer shipments from Wuhan Xinxin	18.5% to 21.5%		
Non-GAAP Operating Expense (1)	\$80.0 to \$84.0 million	\$130 ⁽³⁾ Living Quarters	

- (1) Exclude the effect of foreign exchange, funding of R&D contracts from the government, gain arising from the disposal of living quarters and employee bonus accrual.
- (2) The 2013 planned capital expenditure does not account for additional expenditures for the joint venture company in Beijing, which was established in July 2013. The joint venture company will principally engage in, among other things, the testing, development, design, manufacturing, packaging and sale of integrated circuits.
- (3) In addition, we have budgeted capital expenditures of another \$130 million in 2013 for the construction of living quarters for employees as part of the Company's employee retention program. We plan to either rent out or sell these living quarter units to employees in the future.



Appendix



SMIC Financial Presentation

3Q13 Results Vs Guidance

- <u>889</u>

	3Q 2013 Guidance	3Q 2013 Results	
Revenue including wafer shipments from Wuhan Xinxin	-3% to flat	-1.3%	
Non-GAAP Revenue excluding wafer shipments from Wuhan Xinxin	-1% to +2%	+0.4%	
Gross Margin including wafer shipments from Wuhan Xinxin	17.5% to 20.5%	21.0%	
Non-GAAP Gross Margin excluding wafer shipments from Wuhan Xinxin	18.5% to 21.5%	22.1%	
Operating expenses (1)		I \$63.4 million	
Normalized operating expenses ⁽²⁾	\$81 to \$85 million	\$81.5 million	

- (1) Operating expense as reported on Earning Release.
- (2) Exclude the effect of foreign exchange, funding of R&D contracts from the government and gain arising from the disposal of living quarters.



Capital Expenditures & Depreciation

(US\$ millions)	3Q12	4Q12	1Q13	2Q13	3Q13
Capex	130	102	185	302	169
Depreciation & Amortization	143	140	136	136 I	137





Thank you

Contact us: ir@smics.com

